ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0180 • ACR Convergence 2020

    Clinicopathological Characteristics of Lymphoproliferative Disorders in 232 Patients with Rheumatoid Arthritis in Japan

    Hideto Takada1, Yuko Kaneko2, Kazuhisa Nakano3, Masao Tanaka4, Takao Fujii5, Kazuyoshi Saito6, Naoki Sugimoto1, Shoh Sasaki7, Shuntaro Saito2, Rintaro Saito8, Nobuo Kuramoto5, Yasuo Suzuki7 and Masayoshi Harigai1, 1Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 3The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu-shi, Fukuoka, Japan, 4Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan, 5Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Wakayama, Japan, 6Tobata General Hospital, Kitakyushu, Fukuoka, Japan, 7Division of Rheumatology, Tokai University Hachioji Hospital, Hachioji, Tokyo, Japan, 8Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan

    Background/Purpose: Lymphoproliferative disorders (LPDs) in patients with rheumatoid arthritis (RA) are one of potentially life-threatening complications. However, the diagnosis of LPDs is complicated by the…
  • Abstract Number: 0197 • ACR Convergence 2020

    The Clinical and Laboratory Features of Seronegative Rheumatoid Arthritis with and Without Malignancy

    Misako Higashida-Konishi1, Keisuke Izumi2, Satoshi Hama2, Hiroshi Takei2, Yutaka Okano3 and Hisaji Ohshima2, 1Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Meguro-ku, Tokyo, Japan, 2Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Tokyo, Japan, 3Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Kawasaki, Japan

    Background/Purpose: Patients with elderly onset rheumatoid arthritis(RA) have been reported to be less positive for RF(rheumatoid factor) and ACPA(anti-cyclic citrullinated peptide antibody), and have a…
  • Abstract Number: 0213 • ACR Convergence 2020

    Sustainability of Response to Upadacitinib as Monotherapy or in Combination Among Patients with Rheumatoid Arthritis and Prior Inadequate Response to Conventional Synthetic DMARDs

    Arthur Kavanaugh1, Maya Buch2, Bernard Combe3, Louis Bessette4, In-Ho Song5, Yanna Song6, Jessica Suboticki5 and Peter Nash7, 1Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, 2Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, 3University of Montpellier, Montpellier, France, 4Laval University, Quebec, Canada, 5AbbVie Inc., North Chicago, IL, 6AbbVie Inc., North Chicago,, IL, 7School of Medicine Griffith University, Brisbane, Queensland, Australia

    Background/Purpose: To assess long-term sustainability of responses to upadacitinib (UPA), a JAK inhibitor, with or without background csDMARD(s) in patients (pts) with rheumatoid arthritis (RA).Methods:…
  • Abstract Number: 0230 • ACR Convergence 2020

    Effect of Dose Escalation of Subcutaneous Tocilizumab on Disease Activity in Patients with Rheumatoid Arthritis in a Randomized Controlled Trial

    Nora G. Singer1, Shalini V. Mohan2, Jeffrey Yourish3, Jian Han2, Michael Edwardes4 and Margaret Michalska3, 1Case Western Reserve University and MetroHealth System, Cleveland, 2Genentech, South San Francisco, CA, 3Genentech, Inc., South San Francisco, 4Everest Clinical Research, Ontario, Canada

    Background/Purpose: In patients with rheumatoid arthritis (RA), subcutaneous tocilizumab (TCZ-SC) is administered every 2 weeks (q2w) or every week (qw), based on the patient’s weight…
  • Abstract Number: 0444 • ACR Convergence 2020

    Chronological Order of Decrease of Synovitis, Osteitis and Tenosynovitis in Early Arthritis Patients Receiving First DMARD-treatment

    Xanthe Matthijssen1, Ellis Niemantsverdriet1, Saskia le Cessie1 and Annette van der Helm - van Mil2, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands

    Background/Purpose: Advanced imaging modalities have shown that not only joints but also bones and tendon sheaths can be inflamed at diagnosis of rheumatoid arthritis. We…
  • Abstract Number: 0490 • ACR Convergence 2020

    Fine Specificity Anti-Citrullinated Protein Antibodies as Biomarkers for Prediction of Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease

    Vanessa Kronzer1, Weixing Huang2, Paul Dellaripa3, Sicong Huang4, Vivi Feathers2, Bing Lu5, Christine Iannaccone4, Ritu Gill6, Hiroto Hatabu7, Mizuki Nishino7, Cynthia Crowson8, John Davis1, William Robinson9, Tripta Rughwani9, Jeremy Sokolove10, Michael Weinblatt4, Nancy Shadick11, Tracy J. Doyle12 and Jeffrey Sparks11, 1Mayo Clinic, Rochester, MN, 2Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, 3Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA, Boston, MA, 4Brigham and Women's Hospital, Boston, MA, 5Brigham and Women's Hospital and Harvard Medical School, Newton, MA, 6Beth Israel Deaconess Medical Center, Boston, MA, 7Department of Radiology; Brigham and Women’s Hospital, Boston, 8Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, 9Stanford University, Palo Alto, CA, 10Stanford University, Mountain View, CA, 11Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 12Brigham and Women's Hospital, West Roxbury, MA

    Background/Purpose: Seropositivity for anti-citrullinated protein antibodies (ACPA) has been shown to increase risk for RA-associated interstitial lung disease (RA-ILD). However, RA-related autoantibodies used in clinical…
  • Abstract Number: 0692 • ACR Convergence 2020

    Pre-Operative Opioid Usage Increases Length of Stay for Rheumatoid Arthritis Patients Undergoing Total Hip Arthroplasty and Total Knee Arthroplasty

    Kyle Morse1, Nicole Heinz1, Jeremy Abolade1, Joshua Wright-Chisem1, Linda Russell2, Meng Zhang3, Serene Mirza1, Dana Orange4, Mark Figgie5, Peter Sculco2 and Susan Goodman5, 1Hospital for Special Surgery, New York, 2Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 3Feinstein Institute, Northwell Health, New York, 4Rockefeller University, New York, 5Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Total Hip (THA) and total knee arthroplasty (TKA) are cost-effective procedures that improve the health-related quality of life for patients with advanced symptomatic joint…
  • Abstract Number: 0755 • ACR Convergence 2020

    Exploring the Significance of Anti-Nuclear Antibody Positivity in the Medical Management of Patients with Rheumatoid Arthritis

    Sujaytha Paknikar1, Cynthia Crowson2, John Davis1 and Uma Thanarajasingam1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN

    Background/Purpose: ANA testing has been a well-established screening tool for autoimmune conditions such as SLE. Current practice for classification of RA does not include ANA…
  • Abstract Number: 0773 • ACR Convergence 2020

    The Anti-carbamylated Fibrinogen Response in Rheumatoid Arthritis Targets a Specific Epitope on the γ-chain and Is Associated with a More Active Disease

    Pauline Brevet1, Manuel Freret1, Pascal Rottenberg2, Clément Guillou3, Thierry Lequerre4, Pascal Cosette5, Olivier Boyer2 and Olivier Vittecoq6, 1Inserm U1234 and Rouen University , IRIB, Rouen, France ; Rouen University Hospital, Rheumatology Department, Rouen, France, Rouen, Haute-Normandie, France, 2Inserm U1234 and Rouen University , IRIB, Rouen, France ; Rouen University Hospital, Rheumatology Department, Rouen, France, Rouen, France, 3CNRS 6270, PISSARO, IRIB, Rouen, France ; Centre hospitalo-universitaire de Rouen, Immunology Laboratory, Rouen, France, Rouen, Haute-Normandie, France, 4Rheumatology, University Teaching Hospital, Rouen, France, 5CNRS 6270, PISSARO, IRIB, Rouen, France ; Centre hospitalo-universitaire de Rouen, Immunology Laboratory, Rouen, France, Rouen, France, 6University Hospital of Rouen, Rouen, France

    Background/Purpose: Anti-carbamylated protein autoantibodies (anti-CarP Abs) of IgG and/or IgA isotype have potential diagnostic and prognostic value Carbamylated Fetal Calf Serum (FCS) is the substrate…
  • Abstract Number: 0790 • ACR Convergence 2020

    Vitamin D Polygenetic Risk Score and the Association with RA Autoantibodies Among First-Degree Relatives of RA Subjects

    Elizabeth Bemis1, Kendra Young2, Jennifer Seifert3, Marie Feser4, Kevin D. Deane5, M Kristen Demoruelle6, James O'Dell7, Michael Weisman8, Peter Gregersen9, Richard Keating10, William Robinson11, Jane Buckner12, Carl Langefeld13, Joel Guthridge14, Judith James15, V Michael Holers4 and Jill Norris16, 1Colorado School of Public Health Anschutz Medical Campus, Aurora, CO, 2University of Colorado Denver, Aurora, CO, 3UC Denver, Littleton, CO, 4Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, 52 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, 6University of Colorado, Denver, CO, 7University of Nebraska Medical Center, Omaha, NE, 8Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, 95. Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY, 10Scripps Clinic/Scripps Green Hospital, La Jolla, CA, 11Stanford University, Palo Alto, CA, 12Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, 13Wake Forest School of Medicine, Winston Salem, NC, 14Oklahoma Medical Research Foundation, Oklahoma City, OK, 15Oklahoma Medical Research Foundation, Oklahoma City, 16Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, Colorado

    Background/Purpose: Rheumatoid arthritis (RA) is a complex autoimmune disease whose etiology remains largely unknown.  Vitamin D has been widely studied due to its association with…
  • Abstract Number: 0806 • ACR Convergence 2020

    Identification and Adjustment for Factors Associated with Clinical Response in Rheumatoid Arthritis Clinical Trials to Improve Comparisons of Treatment Efficacy

    Anthony Cordisco1 and Joshua Baker1, 1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Numerous clinical trials have been published in rheumatoid arthritis (RA), but comparing efficacies of disease-modifying anti-rheumatic drugs (DMARDs) is complicated by a lack of…
  • Abstract Number: 0823 • ACR Convergence 2020

    Identifying Physician-Perceived Barriers to a Pragmatic Treatment Trial in Rheumatoid Arthritis

    Haiyan Qu1, Shamly Austin2 and Jasvinder Singh1, 1University of Alabama at Birmingham, Birmingham, AL, 2Gateway Health Plan®, Pittsburgh, PA

    Background/Purpose: The aim of this qualitative research was to identify physician-perceived patient and clinic barriers to patient recruitment in a RA pragmatic trial of anti-TNF…
  • Abstract Number: 0966 • ACR Convergence 2020

    Decoupling Inflammation and Bone Loss in Rheumatoid Arthritis via Schnurri-3

    Zheni Stavre1, JungMin Kim2, Jae-Hyuck Shim2 and Ellen Gravallese3, 1University of Massachusetts Medical School-Rheumatology Division, Worcester, MA, 2University of Massachusetts Medical School, Worcester, MA, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to local and systemic bone loss. TNF is a key mediator of bone loss,…
  • Abstract Number: 1004 • ACR Convergence 2020

    The Incidence, Mortality, and Economic Burden of Potentially Preventable Infections in Rheumatoid Arthritis Patients

    Soumyasri Kambhatla1, Estefania Gauto-Mariotti2 and Augustine Manadan3, 1John H Stroger Hospital of Cook County, Riverside, IL, 2John H. Stroger Jr. Hospital of Cook County, Chicago, IL, 3Rush University Medical Center, Chicago, IL

    Background/Purpose: Streptococcus pneumoniae, Herpes zoster, and influenza infections are common and potentially preventable causes of morbidity and mortality. Vaccinations have been shown to reduce infection…
  • Abstract Number: 1052 • ACR Convergence 2020

    Connective Tissue Disease-Related Interstitial Lung Disease in American Indian/Alaska Native People in Alaska

    Joanna Marco1 and Elizabeth Ferucci2, 1University of Washington, Seattle, WA, 2Alaska Native Tribal Health Consortium, Anchorage, AK

    Background/Purpose: Many connective tissue diseases are known to cause interstitial lung disease (ILD). American Indian/Alaska Native (AI/AN) populations have higher prevalence and severity of a…
  • « Previous Page
  • 1
  • …
  • 144
  • 145
  • 146
  • 147
  • 148
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology